Cholinesterase inhibitors in the treatment of dementia - Are they useful in clinical practice?;Kolinesterasehemmere mot demens - Nyttig i klinisk praksis?

Tidsskrift for den Norske Laegeforening

Volumn 128, Issue 3, 2008, Pages 294-297

  Landmark, Knud ^a   Reikvam, Åsmund ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMIC ACID DERIVATIVE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE; RIVASTIGMINE;

ALZHEIMER DISEASE; DEMENTIA; DIFFUSE LEWY BODY DISEASE; EVIDENCE BASED MEDICINE; HUMAN; MULTIINFARCT DEMENTIA; REVIEW; TIME; TREATMENT OUTCOME;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DEMENTIA; DEMENTIA, VASCULAR; EVIDENCE-BASED MEDICINE; GALANTAMINE; HUMANS; INDANS; LEWY BODY DISEASE; PHENYLCARBAMATES; PIPERIDINES; TIME FACTORS; TREATMENT OUTCOME;

EID: 38949117309     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Bartus RT, Fean RL, Beer B et al. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408-17.
2. Roman GC, Rogers SJ. Donepezil: a clinical review of current and emerging indications. Expert Opin Pharmacother 2004; 5: 161-80.
3. National Institute for Health and Clinical Excellence. TA019 Drugs for Alzheimer's disease: Guidance (html). Donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease. London, NICE, 2003: 1-8.
4. Francis PT, Nordberg A, Arnold SE. A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease? Trends Pharmacol Sci 2005; 26: 104-11.
5. Brækhus A, Engedal K. Vaskulær demens - et dårlig definert begrep. Tidsskr Nor Lægeforen 2004; 124: 1097-9.
6. Purandare N, Burns A, Daly KJ et al. Cerebral emboli as a potential cause of Alzheimer's disease and vascular dementia: case-control study. BMJ 2006; 332: 1119-22.
7. Tohgi H, Abe T, Kimura M et al. Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia. J Neural Transm 1996; 103: 1211-1220.
8. Swartz RH, Sahlas DJ, Black SE. Strategic involvement of cholinergic pathways and executive dysfunction: does location of white matter signal hyperintensities matter? J Stroke Cerebrovasc Dis 2003; 12: 29-36.
9. Legemiddelstatistikk 2006, 2007. Legemiddelforbruket i Norge 2001-2005, 2002-2006. Oslo: Folkehelseinstituttet, 2007.
10. Engedal K. Diagnostikk og behandling av demens. Tidsskr Nor Lægeforen 2002; 122: 540-4.
11. Engedal K, Brækhus A, Gjerstad L. Effekt av legemidler mot demens. Tidsskr Nor Lægeforen 2004; 124: 1641-2.
12. Rogers SL, Farlow MR, Doody RS et al and the Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50: 136-45.
13. Burns A, Rossor M, Hecker J et al. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10: 237-44.
14. Rösler M, Anand R, Cicin-Sain A et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999; 318: 633-8.
15. Wilcock GK, Lilienfield S, Gaens E on behalf of the Galantamine International-1 Study Group. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. BMJ 2000; 321: 1445-9.
16. Tariot PN, Cummings JL, Katz IR et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001; 49: 1590-9.
17. Feldman H, Gauthier S, Hecker J et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001; 57: 613-20.
18. Winblad B, Kilander L, Eriksson S et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006; 367: 1057-65.
19. Raskind MA, Peskind ER, Wessel T et al. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000; 54: 2261-8.
20. Koontz J, Baskys A. Effects of galantamine on working memory and global functioning in patients with mild cognitive impairment: a double-blind placebo-controlled study. Am J Alzheimers Dis Other Demen 2005; 20: 295-302.
21. Ballard C, Margallo-Lana M, Juszczak E et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ 2005; 330: 874-7.
22. Black S, Román GC, Geldmacher DS et al. Efficacy and tolerability of donepezil in vascular dementia. Positive results of a 24 week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003; 34: 2323-32.
23. Wilkinson D, Doody R, Helme R et al. and the Donepezil 308 Study Group. Donepezil in vascular dementia. A randomized, placebo-controlled study. Neurology 2003; 61: 479-86.
24. McKeith I, Del Ser T, Spano PF et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo controlled international study. Lancet 2000; 356: 2031-6.
25. Årsland D. Demens ved Lewy-legemer. Tidsskr Nor Lægeforen 2002; 122: 525-9.
26. Mohs RC, Doody RS, Morris JC et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57: 481-8.
27. Winblad B, Engedal K, Soininen H et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489-95.
28. AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004; 363: 2105-15.
29. Petersen RC, Thomas RG, Grundman M et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005; 352: 2379-88.
30. Nordberg A, Eriksdotter-Jönhagen M, Garlind A et al. Värt ge symptomlindrande läkemedel vid Alzheimers sjukdom. Läkartidningen 2006; 103: 369-71.
31. Engedal K. Utredning av demens og bruk av legemidler mot demens i sykehjem. Tidsskr Nor Lægeforen 2005, 125: 1188-90.
32. Birks J. Cholinesterase inhibitors for Alzheimer's disease (review). The Cochrane Collaboration. The Cochrane Library 2006, Issue 3: 1-75.
33. Blacker D. Mild cognitive impairment - no benefit from vitamin E, little from donepezil. N Engl J Med 2005; 352: 2439-41.
34. Almkvist O, Darreh-Shori T, Stefanova E et al. Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients. Eur J Neurol 2004; 11: 253-61.
35. Blesa R, Davidson M, Kurz A et al. Galantamine provides sustained benefits in patients with «advanced moderate» Alzheimer's disease for at least 12 months. Dement Geriatr Cogn Disord 2003; 15: 79-87.
36. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt H-P et al. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ 2005; 331: 321-7.
37. Takeda A, Loveman E, Clegg A et al. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. Int J Geriatr Psychiatry 2006; 21: 17-28.
38. Hansen RA, Gartlehner G, Lohr KN et al. Functional outcomes of drug treatment in Alzheimer's disease. Drugs Ageing 2007; 24: 155-67.
39. Lanctôt KL, Herrmann N, Yau KK et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analyse. CMAJ 2003; 169: 557-63.
40. Passmore AP, Bayer AJ, Steinhagen-Thiessen E. Cognitive, global and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials. J Neurol Sci 2005; 229-230: 141-6.
41. Olsen CE, Poulsen HD, Lublin HKF. Drug therapy of dementia in elderly patients. A review. Nord J Psychiatry 2005; 59: 71-7.
42. Erkinjuntti T, Román G, Gauthier S. Treatment of vascular dementia - evidence from clinical trials with cholinesterase inhibitors. J Neurol Sci 2004; 226: 63-6.
43. Australian Adverse Drug Reactions Committee (ADRAC). Cholinesterase inhibitors and cardiac arrhythmias. Australian Adverse Drug Reactions Bulletin 2004; 23: 5.
44. Suleyman T, Tevfik P, Abdulkadir et al. Complete atrioventricular block and ventricular tachyarrhythmia associated with donepezil. Emerg Med J 2006; 23: 641-2.
45. FDA Alert for Healthcare Professionals. Galantamine hydrobromide (marketed as Razadyne, formely Reminyl). FDA Alert 5/2005. Washington D.C.: FDA, 2005.
46. ADRAG. Deaths with galantamine in mild cognitive impairment studies. Australian Adverse Drug Reactions Bulletin 2006; 25.
47. www. clinicalstudyresults.org/drugdetails/ (9.11.2006).
48. Sammanfattning av SBU: s rapport om demenssjukdomar. En systematisk litteraturöversikt. Stockholm: SBU, 2006: 3-75.
49. Burback D, Molnar FJ, St John P et al. Key methodological features of randomized controlled trials of Alzheimer's disease therapy. Minimal clinically important difference, sample size and trial duration. Dement Geriatr Cogn Disord 1999; 10: 534-40.
50. Andersen SE. Specifikke lægemidler mod Alzheimers sygdom. Rational Farmakoterapi2007; nr. 2.
51. Attia J, Schofield P. What now for Alzheimer's disease? An epidemiological evaluation of the AD2000 trial. Aust Prescr 2005; 28: 134-5.
52. Schneider LS, Olin JT, Lyness SA et al. Eligibility of Alzheimer's disease clinic patients for clinical trials. J Am Geriatr Soc 1997; 45: 923-8.
53. Lexchin J, Bero LA, Djulbegovic B et al. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003; 326: 1167-70.
54. Als-Nielsen B, Chen W, Gluud C et al. Association of funding and conclusions in randomized drug trials. A reflection of treatment effect or adverse events? JAMA 2003; 290: 921-8.
55. Gauthier SG. Alzheimer's disease: the benefits of early treatment. Eur J Neurol 2005; 12 (suppl 3): 11-6.
56. Pelosi AJ, McNulty SV, Jackson GA. Role of cholinesterase inhibitors in dementia care needs rethinking. BMJ 2006; 333: 491-3.
57. Grundman M. Vitamin E and Alzheimers disease: the basis for additional clinical trials. Am J Clin Nutr 2000; 71: 630S-6S.
58. Ritchie K, Dupuy A-M. The current status of APO E4 as a risk factor for Alzheimers disease: an epidemiological perspective. Int J Geriatr Psychiatry 1999; 14: 695-700.
59. Hogan DB. Donepezil for severe Alzheimer's disease. Lancet 2006; 367: 1031-2.
60. Ritchie CW, Ames D, Clayton T et al. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Am J Geriatr Psychiatry 2004; 12: 358-69.